Wegovy for weight loss: the facts without the hype

The biggest myth: Wegovy does the work so you don't have to

The most persistent misconception about Wegovy for weight loss is that the injection replaces everything else. People see the trial headlines (15% average weight reduction) and assume the medicine handles it independently. It doesn't, and the licence is explicit on this: Wegovy is approved for use alongside a reduced-calorie diet and increased physical activity. The trial participants who achieved those results were enrolled in a structured lifestyle programme throughout. The medicine changes the biology; the behaviour change is still part of the picture.

What semaglutide actually does is act on GLP-1 receptors in the brain and gut, and if you want to understand how semaglutide produces weight loss at a biological level, the mechanism is worth reading about before you start. It slows how quickly food leaves your stomach, increases feelings of fullness after eating, and reduces appetite signals between meals. For many people this makes the behavioural side considerably easier, you're not fighting constant hunger while trying to eat less. But if the diet and activity component is absent, results are meaningfully smaller. That context matters when you're deciding whether this treatment fits your life.

It's also worth knowing that weight tends to return when treatment stops, particularly without maintained lifestyle habits. How long Wegovy takes to produce noticeable weight loss is a question our prescribers hear often, and the honest answer is that the early weeks are about tolerability as much as results.

What the STEP 1 trial actually measured, and the 7.2mg update

The foundational evidence for Wegovy in weight management comes from the STEP clinical programme. STEP 1, published in the New England Journal of Medicine, followed 1,961 adults with obesity or overweight plus at least one weight-related condition over 68 weeks. Those receiving 2.4mg semaglutide weekly lost an average of around 15% of body weight against roughly 2.4% in the placebo group. That is a substantial and meaningful difference.

Since those original results, the evidence base has grown. In January 2026 the MHRA approved a higher 7.2mg maintenance dose of Wegovy, and on 14 April 2026 it approved a dedicated single-dose 7.2mg pen (one pre-set weekly injection) for adults with a BMI of 30 or above. Trials at this dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide. If you want a cost comparison across weight-loss treatments available in the UK, that context matters when weighing up your options.

One detail that gets lost in headlines: trial results are averages. Some participants lost considerably more; others less. Individual response depends on starting weight, adherence, metabolic factors and how well the titration schedule is tolerated. No two people's journeys look identical.

Who Wegovy is licensed for in the UK, and how the dose builds

Under its UK licence, Wegovy is intended for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Being within these parameters doesn't guarantee a prescription, a prescriber looks at the whole picture, including medications you already take, your medical history and any contraindications.

The dose schedule starts at 0.25mg weekly and steps up roughly every four weeks, moving through 0.5mg, 1mg and 1.7mg before reaching the 2.4mg maintenance dose. The titration exists to give your body time to adjust, since the most common side effects (nausea, loose stools, reflux) are most pronounced during increases and tend to settle. The NHS patient information for semaglutide, which the NHS medicines page covers in detail, is a reliable guide to what to expect at each stage.

Wegovy is a Black Triangle medicine, meaning it is subject to additional MHRA monitoring while post-market safety data continues to accumulate. That's standard for newer medicines and not a cause for alarm, it means any emerging patterns get picked up and communicated quickly. People sometimes ask whether Wegovy affects fluid balance, and you can find a clear answer on our page looking at whether Wegovy acts as a diuretic. You can also read more about semaglutide's clinical profile if you want the fuller picture before your consultation.

Wegovy on the NHS versus going private

NICE recommends semaglutide (Wegovy) for NHS use, but with significant conditions: it is approved for a maximum of two years, within a specialist weight management service providing multidisciplinary support, and for adults meeting specific BMI and comorbidity thresholds. In practice, waiting lists for specialist services are long across much of England, and availability varies considerably by area. Scotland, Wales and Northern Ireland operate under different criteria.

Private treatment through a regulated online pharmacy removes the waiting list and the specialist-service requirement, while keeping the clinical assessment that the law requires. A GPhC-registered prescriber reviews your consultation the same day at nume, a real clinician reads your answers, not software. Your prescription and medication are dispatched that day if you order before noon, arriving via DPD the next working day in plain, unbranded packaging. It's the kind of timing that works around ordinary life, a morning before the school run rather than a six-month wait for a clinic slot.

If you're weighing up the private route, our overview of Wegovy as a weight-loss medicine covers the access and clinical detail side by side. And if you're still deciding which treatment might suit your circumstances, the free consultation is the right place to start, there's no obligation, and a prescriber will give you an honest assessment.